Search results
Added:
3 years ago
Added:
3 years ago
Dr R Scott Wright (Mayo Clinic, Rochester, MN, US) summarises a pooled analyses of phase 3 studies showing how Inclisiran potently and durably reduces Ldl-c.
Questions:
1. What prompted the study?
2. How does Inclisiran work?
3. What is the study design?
4. Who were the patients?
5. What were the efficacy results?
6. What were the safety findings?
7. What are the implications of this…
View more
Added:
3 years ago
Proprotein convertases are proteolytic enzymes that activate proteins by post-translational alterations in protein structure. Proprotein convertase subtilisin/kexin 9 (PCSK9) is a proprotein convertase that binds and inactivates the low-density lipoprotein (LDL) receptor on the surface of hepatocytes resulting in higher levels of serum LDL cholesterol (LDL-C).1 Over-expression of PCSK9 leads to a…
View more
Added:
3 years ago
Proprotein convertase subtilisin/kexin type 9 (PCSK9), discovered in 2003, is a circulating protein produced predominantly in the liver that plays a significant role in the recycling of LDL receptors (LDLRs).1,2 The LDLR, which normally recycles about 100 times in its lifetime, is the primary pathway for LDL-cholesterol (LDL-C) clearance from circulation. Plasma PCSK9 binds to LDLRs along with…
View more